BCRX Biocryst Pharmaceuticals Inc

Price (delayed)

$5.71

Market cap

$1.17B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.25

Enterprise value

$1.86B

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of ...

Highlights
Biocryst Pharmaceuticals's gross profit has increased by 33% YoY and by 4.5% from the previous quarter
BCRX's revenue is up by 33% YoY and by 3.6% QoQ
The net income has declined by 22% year-on-year but it has increased by 2.6% since the previous quarter
BCRX's EPS is down by 19% YoY but it is up by 3.1% from the previous quarter
BCRX's equity has dropped by 69% year-on-year and by 6% since the previous quarter
BCRX's debt is up by 17% YoY and by 2.2% QoQ

Key stats

What are the main financial stats of BCRX
Market
Shares outstanding
204.81M
Market cap
$1.17B
Enterprise value
$1.86B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
3.41
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.86
Earnings
Revenue
$317.56M
EBIT
-$124.42M
EBITDA
-$122.79M
Free cash flow
-$112.21M
Per share
EPS
-$1.25
Free cash flow per share
-$0.59
Book value per share
-$2.17
Revenue per share
$1.67
TBVPS
$2.76
Balance sheet
Total assets
$522.92M
Total liabilities
$933.91M
Debt
$845.43M
Equity
-$410.99M
Working capital
$411.7M
Liquidity
Debt to equity
-2.06
Current ratio
5.54
Quick ratio
4.99
Net debt/EBITDA
-5.64
Margins
EBITDA margin
-38.7%
Gross margin
98.3%
Net margin
-74.4%
Operating margin
-33.8%
Efficiency
Return on assets
-44.8%
Return on equity
N/A
Return on invested capital
-12%
Return on capital employed
-28.8%
Return on sales
-39.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BCRX stock price

How has the Biocryst Pharmaceuticals stock price performed over time
Intraday
-1.89%
1 week
-3.55%
1 month
3.82%
1 year
-39.51%
YTD
-4.67%
QTD
-4.67%

Financial performance

How have Biocryst Pharmaceuticals's revenue and profit performed over time
Revenue
$317.56M
Gross profit
$312.04M
Operating income
-$107.35M
Net income
-$236.35M
Gross margin
98.3%
Net margin
-74.4%
The operating margin has grown by 48% YoY and by 8% from the previous quarter
Biocryst Pharmaceuticals's gross profit has increased by 33% YoY and by 4.5% from the previous quarter
BCRX's revenue is up by 33% YoY and by 3.6% QoQ
BCRX's operating income is up by 30% YoY and by 4.9% QoQ

Growth

What is Biocryst Pharmaceuticals's growth rate over time

Valuation

What is Biocryst Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
3.41
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.86
BCRX's EPS is down by 19% YoY but it is up by 3.1% from the previous quarter
BCRX's equity has dropped by 69% year-on-year and by 6% since the previous quarter
The P/S is 84% lower than the 5-year quarterly average of 21.2 and 38% lower than the last 4 quarters average of 5.5
BCRX's revenue is up by 33% YoY and by 3.6% QoQ

Efficiency

How efficient is Biocryst Pharmaceuticals business performance
The company's return on assets fell by 27% YoY
The ROIC rose by 10% QoQ and by 8% YoY
BCRX's ROS is up by 9% from the previous quarter and by 3.7% YoY

Dividends

What is BCRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BCRX.

Financial health

How did Biocryst Pharmaceuticals financials performed over time
Biocryst Pharmaceuticals's total assets is 44% lower than its total liabilities
The total liabilities has grown by 17% YoY
Biocryst Pharmaceuticals's quick ratio has decreased by 14% YoY
BCRX's equity has dropped by 69% year-on-year and by 6% since the previous quarter
BCRX's debt to equity is up by 31% year-on-year and by 3.3% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.